https://pipelinereview.com/neoadjuvant-opdivo-nivolumab-plus-chemotherapy-significantly-improves-pathologic-complete-response-in-patients-with-resectable-non-small-cell-lung-cancer-in-phase-3-checkmate-816-trial/